Madrigal Pharmaceuticals, Inc.
MDGL US5588681057
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
-23% | 222% | -19% | 36% | 2% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Sibold William John CEO |
445.63 USD |
7,279 Sold |
3,243,741 USD |
09/09/2025 | 09/09/2025 |
Sibold William John CEO |
401.00 USD |
1,131 Sold |
453,531 USD |
21/08/2025 | 21/08/2025 |
Sibold William John CEO |
400.03 USD |
6,485 Sold |
2,594,225 USD |
21/08/2025 | 21/08/2025 |
Kelley Shannon T SR OFF |
375.75 USD |
190 Sold |
71,393 USD |
18/08/2025 | 18/08/2025 |
Kelley Shannon T SR OFF |
372.44 USD |
252 Sold |
93,855 USD |
18/08/2025 | 18/08/2025 |
Kelley Shannon T SR OFF |
370.06 USD |
84 Sold |
31,085 USD |
18/08/2025 | 18/08/2025 |
Kelley Shannon T SR OFF |
376.62 USD |
42 Sold |
15,818 USD |
18/08/2025 | 18/08/2025 |
Kelley Shannon T SR OFF |
369.64 USD |
126 Sold |
46,575 USD |
18/08/2025 | 18/08/2025 |
Kelley Shannon T SR OFF |
358.66 USD |
458 Sold |
164,266 USD |
18/08/2025 | 18/08/2025 |
Kelley Shannon T SR OFF |
371.35 USD |
84 Sold |
31,193 USD |
18/08/2025 | 18/08/2025 |